Browse the corpus

Intrapleural catheters, most commonly indwelling pleural catheters (IPCs), are tunneled silicone drainage systems used for long-term management of recurrent pleural effusions, particularly malignant pleural effusions and trapped-lung physiology. Placement typically occurs under local anesthesia in an outpatient or bedside setting, enabling ambulatory management through intermittent drainage using a one-way valve connected to vacuum bottles. Tunneled design with a polyester cuff encourages tissue ingrowth and lowers infection risk while maintaining catheter stability. Continuous or intermittent drainage relieves dyspnea, reduces hospital utilization, and improves quality of life in appropriately selected patients. Spontaneous pleurodesis may occur during ongoing drainage, eliminating the need for further intervention in some cases. Clinical evidence demonstrates high success rates and fewer repeat invasive procedures compared with conventional chemical pleurodesis when patient selection aligns with physiologic characteristics and disease progression. Participants in this course strengthen their knowledge of patient selection, catheter placement considerations, and management strategies for complications associated with intrapleural catheters. Educational content emphasizes recognition of trapped lung physiology, appropriate drainage schedules, and early identification of infection, blockage, or catheter malfunction. Instruction also highlights outpatient monitoring, discharge planning, and longitudinal follow-up strategies that support safe long-term use. Collaboration among clinicians, nursing professionals, respiratory therapists, and interventional specialists improves care coordination, promotes timely management of complications, and enhances patient education on home drainage. Interprofessional teamwork ultimately supports improved symptom control, reduced hospitalizations, greater patient satisfaction, and better overall clinical outcomes for individuals with recurrent pleural effusions. Objectives: Identify appropriate candidates for intrapleural catheter placement, including patients with malignant pleural effusion or trapped lung who are unlikely to benefit from pleurodesis. Assess ongoing symptom burden, drainage volume trends, and signs of complications such as cellulitis, empyema, or catheter obstruction.

Objectives: Identify appropriate candidates for intrapleural catheter placement, including patients with malignant pleural effusion or trapped lung who are unlikely to benefit from pleurodesis. Assess ongoing symptom burden, drainage volume trends, and signs of complications such as cellulitis, empyema, or catheter obstruction. Screen patients for contraindications to placement, including uncontrolled coagulopathy, active pleural infection, or poor performance status incompatible with outpatient management. Collaborate with pulmonology, thoracic surgery, oncology, interventional radiology, nursing, and home health teams to ensure comprehensive care. Access free multiple choice questions on this topic.

Pleural effusion is a common condition in emergency departments worldwide and a frequent reason for consultation with pulmonology. In the United States, nearly 1.5 million cases of pleural effusion are diagnosed each year. Congestive heart failure (CHF) is the most common cause, followed by pneumonia. Traditionally, pleural effusions are classified as transudates or exudates. Transudative effusions result from increased hydrostatic pressure with intact capillary membranes, whereas exudative effusions arise from capillary damage secondary to inflammatory or malignant processes.[1][2][3][4][5] Most pleural effusions resolve following correction of the underlying cause and therapeutic thoracentesis. However, a substantial proportion recur rapidly or remain refractory, leading to repeated hospital visits, patient discomfort, and increased healthcare use. Malignant pleural effusions (MPEs) constitute the most common cause of recurrent pleural effusions, with lung cancer, breast cancer, and lymphoma being the predominant etiologies. Among nonmalignant pleural effusions, refractory CHF and hepatic hydrothorax are the leading causes.[6][7][8] Recent literature has shifted the management paradigm from repeated thoracenteses to definitive pleural interventions for recurrent effusions. Indwelling pleural catheters (IPCs) have emerged as an effective strategy, providing durable symptom relief, reducing hospital stay, and enabling outpatient-based management (see Image. Indwelling Pleural Catheter System).[9][10][11][12] Although initially developed for MPEs, growing evidence supports the use of IPCs in selected nonmalignant pleural effusions, particularly refractory CHF and hepatic hydrothorax, with acceptable safety profiles.[13][14][15][16] Results from randomized controlled trials have demonstrated symptom control comparable to talc pleurodesis, with the added advantages of shorter hospitalization and the potential for spontaneous pleurodesis.[10][11][12] Contemporary international guidelines now endorse IPCs as a first-line option for recurrent MPEs and a reasonable alternative in selected nonmalignant effusions, emphasizing shared decision-making and patient-centered care.[9][17][18] Additionally, they have also been found to cause less pain and are much better tolerated than the older chest tubes.[19]

Infection As with a long-term urinary catheter, bacteria can colonize an IPC. The pleural fluid culture will be positive, but there will be no signs or symptoms, nor a pathognomonic biochemical profile, characteristic of empyema. In some patients, diagnosing pleural infection can be challenging, as most MPEs have low pH, elevated lactate dehydrogenase, and low glucose. To date, the incidence of IPC-related pleural infection is unknown. Additionally, the diagnostic criteria for pleural infection are the same for patients with IPCs. Skin flora, most commonly Staphylococcus aureus, is reported in case reports, followed by Pseudomonas aeruginosa. Fsych et al reported that the results from a large multicenter trial involving 1021 patients showed an infection incidence of 4.8% and a mortality rate of 0.29%.[33] Infection typically occurs 6 to 8 weeks post-insertion and is more likely attributable to post-insertion care than to arterial colonization during the procedure. Interestingly, IPC-related pleural infection often results in pleurodesis, particularly with staphylococcal infection. There is no documented increase in the risk of pleural infection with IPCs in immunocompromised patients. This is well documented in patients with hematological malignancies on chemotherapy. Catheter Tract Metastasis Patients treated with IPC for MPEs can develop painful nodules near the insertion site or the point of entry into the parietal pleura. Treatment is analgesia and radiotherapy. Mesothelioma is notorious for causing catheter tract metastasis. The cause of this complication remains unknown.[19] Residual Loculated Effusions The presence of an IPC is postulated to promote fibrin deposition, which can lead to the formation of loculations, thereby rendering the IPC nonfunctional. This complication usually happens at least 8 weeks postinsertion. Treatment is fibrinolytic therapy with tissue plasminogen activator through the IPC. This is usually very successful but carries a small risk of significant pleural hemorrhage. Malnutrition Cachexia is very common in those with cancer. Because pleural fluid is rich in protein, the risk of malnutrition is thought to be substantial. A prospective trial followed patients with IPC for 1 year, but the results showed no significant risk of malnutrition. Blockage

The presence of an IPC is postulated to promote fibrin deposition, which can lead to the formation of loculations, thereby rendering the IPC nonfunctional. This complication usually happens at least 8 weeks postinsertion. Treatment is fibrinolytic therapy with tissue plasminogen activator through the IPC. This is usually very successful but carries a small risk of significant pleural hemorrhage. Malnutrition Cachexia is very common in those with cancer. Because pleural fluid is rich in protein, the risk of malnutrition is thought to be substantial. A prospective trial followed patients with IPC for 1 year, but the results showed no significant risk of malnutrition. Blockage Fibrous tissue grows around and within the IPC, obstructing several openings. This tissue seldom affects drainage. A complete blockage is rare, occurring in fewer than 5% of cases. A mild blockage usually responds to saline flushes.[34] Catheter Fracture This usually happens when an IPC is removed. The polyester cuff promotes inflammation and fibrosis, thereby leading to tight catheter anchoring. The risk is estimated at approximately 10%. This is usually managed by surgical exploration or by leaving the catheter fragments in situ. No complications have been reported with retained IPC fragments.[34]

Effective management of IPCs requires procedural expertise, strategic patient selection, and coordinated interdisciplinary care. Physicians and advanced practitioners must assess candidacy, particularly in patients with malignant pleural effusion or trapped lung, while evaluating performance status, expected survival, and goals of care. Technical competence in sterile placement, tunneling technique, and complication avoidance is essential to minimize pneumothorax, infection, and catheter malfunction. Strategic planning includes determining drainage schedules, monitoring for spontaneous pleurodesis, and identifying early signs of infection or loculation. Clear documentation of catheter type, placement date, and drainage protocol supports safe longitudinal management across care settings. Nurses play a pivotal role in patient education, aseptic drainage technique, symptom monitoring, and reinforcement of home-care instructions, which are critical for preventing infection and maintaining catheter patency. Pharmacists contribute by optimizing analgesia, guiding antimicrobial therapy when infection is suspected, and reviewing anticoagulation management around placement. Interprofessional communication, particularly during discharge planning and transitions to outpatient or hospice care, ensures continuity of drainage supplies, follow-up imaging, and timely evaluation of complications. Collaboration among pulmonology, thoracic surgery, oncology, interventional radiology, palliative care, and home health services enhances patient-centered outcomes, improves symptom control, reduces hospital utilization, and strengthens overall team performance in the management of pleural effusions.